How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Standard

How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? / Catapano, Alberico L; Daccord, Magdalena; Damato, Elaine; Humphries, Steve E; Neely, R. Dermot G.; Nordestgaard, Børge G.; Pistollato, Michele; Steinhagen-Thiessen, Elisabeth.

I: Atherosclerosis, Bind 349, 2022, s. 136-143.

Publikation: Bidrag til tidsskriftKommentar/debatForskningfagfællebedømt

Harvard

Catapano, AL, Daccord, M, Damato, E, Humphries, SE, Neely, RDG, Nordestgaard, BG, Pistollato, M & Steinhagen-Thiessen, E 2022, 'How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?', Atherosclerosis, bind 349, s. 136-143. https://doi.org/10.1016/j.atherosclerosis.2022.02.013

APA

Catapano, A. L., Daccord, M., Damato, E., Humphries, S. E., Neely, R. D. G., Nordestgaard, B. G., Pistollato, M., & Steinhagen-Thiessen, E. (2022). How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis, 349, 136-143. https://doi.org/10.1016/j.atherosclerosis.2022.02.013

Vancouver

Catapano AL, Daccord M, Damato E, Humphries SE, Neely RDG, Nordestgaard BG o.a. How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)? Atherosclerosis. 2022;349:136-143. https://doi.org/10.1016/j.atherosclerosis.2022.02.013

Author

Catapano, Alberico L ; Daccord, Magdalena ; Damato, Elaine ; Humphries, Steve E ; Neely, R. Dermot G. ; Nordestgaard, Børge G. ; Pistollato, Michele ; Steinhagen-Thiessen, Elisabeth. / How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?. I: Atherosclerosis. 2022 ; Bind 349. s. 136-143.

Bibtex

@article{6037b0ac04664577aa22c4c77ec1747c,
title = "How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?",
abstract = "Background and aims: Elevated concentrations of Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aims to investigate the clinical utility for patients, and the economic benefit to healthcare systems and society of measuring Lp(a) concentrations more widely today. Methods: We conducted a structured literature review to identify the economic and health benefits and costs of measuring the Lp(a) concentration, potential barriers hindering the uptake of the measure, and potential solutions to address them. These findings were then discussed in an advisory board attended by experts and patient organisations. Results: It was found that if Lp(a) concentration is measured more widely today, patients, healthcare system and society would experience clinical and economic benefits even before specific Lp(a) lowering pharmacological treatments become available. Furthermore, a wider uptake of the Lp(a) measurement would support the development of epidemiological data. Conclusions: For Lp(a) measurement to be more widely used, key barriers which are hindering its uptake need to be addressed. These include i) the perception that the measure may have limited clinical value, ii) lack of awareness on Lp(a), iii) lack of data on the CV benefit of reducing Lp(a), iv) technical and clinical guidelines barriers, and v) healthcare system barriers. Scientific communities and industry should collaborate to address technical challenges and deficiencies in clinical guidelines. However, policy intervention will be crucial for national ASCVD plans to acknowledge the importance of Lp(a).",
keywords = "Atherosclerotic cardiovascular disease (ASCVD), Barriers to measurement uptake, Clinical benefit, Lipoprotein (a) [Lp(a)], Lp(a) measurement, Policy intervention",
author = "Catapano, {Alberico L} and Magdalena Daccord and Elaine Damato and Humphries, {Steve E} and Neely, {R. Dermot G.} and Nordestgaard, {B{\o}rge G.} and Michele Pistollato and Elisabeth Steinhagen-Thiessen",
note = "Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
doi = "10.1016/j.atherosclerosis.2022.02.013",
language = "English",
volume = "349",
pages = "136--143",
journal = "Journal of atherosclerosis research",
issn = "1567-5688",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular disease (CVD)?

AU - Catapano, Alberico L

AU - Daccord, Magdalena

AU - Damato, Elaine

AU - Humphries, Steve E

AU - Neely, R. Dermot G.

AU - Nordestgaard, Børge G.

AU - Pistollato, Michele

AU - Steinhagen-Thiessen, Elisabeth

N1 - Publisher Copyright: © 2022 Elsevier B.V.

PY - 2022

Y1 - 2022

N2 - Background and aims: Elevated concentrations of Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aims to investigate the clinical utility for patients, and the economic benefit to healthcare systems and society of measuring Lp(a) concentrations more widely today. Methods: We conducted a structured literature review to identify the economic and health benefits and costs of measuring the Lp(a) concentration, potential barriers hindering the uptake of the measure, and potential solutions to address them. These findings were then discussed in an advisory board attended by experts and patient organisations. Results: It was found that if Lp(a) concentration is measured more widely today, patients, healthcare system and society would experience clinical and economic benefits even before specific Lp(a) lowering pharmacological treatments become available. Furthermore, a wider uptake of the Lp(a) measurement would support the development of epidemiological data. Conclusions: For Lp(a) measurement to be more widely used, key barriers which are hindering its uptake need to be addressed. These include i) the perception that the measure may have limited clinical value, ii) lack of awareness on Lp(a), iii) lack of data on the CV benefit of reducing Lp(a), iv) technical and clinical guidelines barriers, and v) healthcare system barriers. Scientific communities and industry should collaborate to address technical challenges and deficiencies in clinical guidelines. However, policy intervention will be crucial for national ASCVD plans to acknowledge the importance of Lp(a).

AB - Background and aims: Elevated concentrations of Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aims to investigate the clinical utility for patients, and the economic benefit to healthcare systems and society of measuring Lp(a) concentrations more widely today. Methods: We conducted a structured literature review to identify the economic and health benefits and costs of measuring the Lp(a) concentration, potential barriers hindering the uptake of the measure, and potential solutions to address them. These findings were then discussed in an advisory board attended by experts and patient organisations. Results: It was found that if Lp(a) concentration is measured more widely today, patients, healthcare system and society would experience clinical and economic benefits even before specific Lp(a) lowering pharmacological treatments become available. Furthermore, a wider uptake of the Lp(a) measurement would support the development of epidemiological data. Conclusions: For Lp(a) measurement to be more widely used, key barriers which are hindering its uptake need to be addressed. These include i) the perception that the measure may have limited clinical value, ii) lack of awareness on Lp(a), iii) lack of data on the CV benefit of reducing Lp(a), iv) technical and clinical guidelines barriers, and v) healthcare system barriers. Scientific communities and industry should collaborate to address technical challenges and deficiencies in clinical guidelines. However, policy intervention will be crucial for national ASCVD plans to acknowledge the importance of Lp(a).

KW - Atherosclerotic cardiovascular disease (ASCVD)

KW - Barriers to measurement uptake

KW - Clinical benefit

KW - Lipoprotein (a) [Lp(a)]

KW - Lp(a) measurement

KW - Policy intervention

U2 - 10.1016/j.atherosclerosis.2022.02.013

DO - 10.1016/j.atherosclerosis.2022.02.013

M3 - Comment/debate

C2 - 35292153

AN - SCOPUS:85126828139

VL - 349

SP - 136

EP - 143

JO - Journal of atherosclerosis research

JF - Journal of atherosclerosis research

SN - 1567-5688

ER -

ID: 318032091